drugset
drugset / Trial / NCT04830644

A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.

NCT04830644 ↗

Phase 2 Unknown 144 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of iguratimod compared to placebo in patients with active primary Sjogren's Syndrome.

Timeline

Start
2021-03-22
Primary completion
2022-04
Completion
2022-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Iguratimod Small molecule 10 mg Oral
Subject Iguratimod Small molecule 20 mg Oral
Subject Iguratimod Small molecule 25 mg Oral

Indications

Sjogren syndrome